MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2023 International Congress

    Quantification of Striatal and Extrastriatal Dopamine Transporters with [18F]PR04.MZ and [18F] PI- 2620 PET in Patients with Progressive Supranuclear Palsy.

    X. Pizarro, P. Salles, P. Chana, V. Kramer (santiago, Chile)

    Objective: We aim to evaluate the differences in striatal subregional dopamine transporter loss between Parkinson disease (PD) and progressive supranuclear palsy (PSP) of any stage…
  • 2023 International Congress

    Novel utilization of deep brain stimulation in the pedunculopontine nucleus for treatment of childhood-onset dystonia

    J. Davies, J. Kurtz, J. Maclean, T. Sanger, M. Liker, J. Olaya (Orange, USA)

    Objective: Investigate the efficacy of deep brain stimulation (DBS) in the pedunculopontine nucleus (PPN) for the treatment of dystonia in pediatric patients. Background: Deep brain…
  • 2023 International Congress

    Impact of non-pharmacological strategies on progression in Parkinson’s Disease and Cognitive Impairment.

    MAG. Medrano-Delgado, DR. Aguila-Godinez, MF. Ruiz-Mafud, LG. Lira-Juárez, EC. Santiago Delacruz, A. Domínguez-García, AJ. Hernández-Medrano, AY. Regalado-Mustafá, MF. Medina-Pérez, G. Hernandez-Armesto, K. Talavera-Laguna, A. Herrera-Ruiz, J. García-Hernández, DP. Romero-Terán, A. Alcocer-Salas, G. Cerda-Hernández, A. Abundes-Corona, M. Rodríguez-Violante, A. Cervantes-Arriaga (Ciudad de Mexico, Mexico)

    Objective: to determine the Impact of non-pharmacological strategies on progression in Parkinson's Disease and Cognitive Impairment. Background: PD is the second most common neurodegenerative disorder,…
  • 2023 International Congress

    Development and Validation of an Algorithm to Automatically Assess Motor Symptoms of Parkinson’s Disease

    S. Sekimoto, G. Oyama, Y. Nonomiya, T. Hayashi, M. Soshi, S. Chiba, N. Hattori (Bunkyo-ku, Japan)

    Objective: To assist non-specialists in evaluating patients with advanced Parkinson's disease who have difficulty visiting specialists’ hospitals, we developed an algorithm to automatically rate the…
  • 2023 International Congress

    Experience of the LARGE-PD protocol in a health center in Buenos Aires, Argentina

    N. Gonzalez Rojas, E. Gatto, I. Mata, C. Perandones, M. Inca, M. Cesarini, G. da Prat, J. Etcheverry (Buenos Aires, Argentina)

    Objective: Disseminate and inform the activity of the Latin American Research Consortium on the Genetics of Parkinson's Disease (LARGE-PD) in Argentina. Background: The LARGE-PD consortium…
  • 2023 International Congress

    Determination of metabotropic glutamate 2 receptor distribution with [3H]-LY-341,495 in hemi-parkinsonian rats with L-DOPA-induced dyskinesia

    E. Kim, J. Shaqfah, I. Frouni, P. Huot (Montreal, Canada)

    Objective: To determine the distribution and density of metabotropic glutamate 2 (mGlu2) receptors in the motor loop of the basal ganglia in 6-hydroxydopamine (6-OHDA)-lesioned rats…
  • 2023 International Congress

    Myocardial sympathetic denervation biomarkers for early detection of prodromal DLB

    M. Park, J. An (Daegu, Republic of Korea)

    Objective: Because of the time course of detecting DLB symptoms and signs, DLB is poorly diagnosed and hardly differentiate from AD, especially in early stage…
  • 2023 International Congress

    Huntington’s disease in Senegal Epidemiological and clinical aspects

    M. Fall (Dakar, Senegal)

    Objective: The objective of this study was to describe the epidemiological and clinical aspects of Huntington's disease in Senegal. Background: Huntington′s disease (HD) is an…
  • 2023 International Congress

    Identification of reproducible metabolites for Parkinson’s Disease diagnosis using clinical data and computational modelling

    X. Luo, YJ. Liu, A. Balck, C. Klein, R. Fleming (Galway, Ireland)

    Objective: To identify replicated metabolic markers of Parkinson’s Disease (PD) diagnosis from metabolomic studies and predict additional metabolic markers using computational metabolic modelling. Background: Reported metabolic markers of…
  • 2023 International Congress

    The effect of anti- Parkinson’s disease granules and probiotics on gastrointestinal motility in the mouse model of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine -induced Parkinson’s disease

    X. Zhao, J. Yang (Shanghai, China)

    Objective: To investigate the effect of anti- Parkinson’s disease (anti-PD granules) and probiotics on gastrointestinal motility in the mouse model of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine( MPTP )-induced PD. Background:…
  • « Previous Page
  • 1
  • …
  • 126
  • 127
  • 128
  • 129
  • 130
  • …
  • 186
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley